-$0.33 EPS Expected for Inovio Pharmaceuticals, Inc. (NASDAQ:INO) This Quarter

Analysts expect Inovio Pharmaceuticals, Inc. (NASDAQ:INO) to post earnings of ($0.33) per share for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Inovio Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.25) and the lowest estimate coming in at ($0.42). Inovio Pharmaceuticals posted earnings of ($0.22) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 50%. The business is expected to report its next quarterly earnings report on Monday, November 8th.

According to Zacks, analysts expect that Inovio Pharmaceuticals will report full year earnings of ($1.38) per share for the current fiscal year, with EPS estimates ranging from ($1.54) to ($1.18). For the next financial year, analysts forecast that the company will report earnings of ($0.98) per share, with EPS estimates ranging from ($2.73) to $1.48. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Inovio Pharmaceuticals.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Monday, August 9th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.14). The firm had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $1.21 million. Inovio Pharmaceuticals had a negative net margin of 2,193.30% and a negative return on equity of 42.42%. The business’s revenue was up 2.2% compared to the same quarter last year. During the same quarter last year, the business earned ($0.83) EPS.

Several equities research analysts recently commented on the company. Jefferies Financial Group assumed coverage on Inovio Pharmaceuticals in a report on Thursday, June 24th. They issued a “hold” rating and a $9.00 price target for the company. Bank of America cut Inovio Pharmaceuticals from a “neutral” rating to an “underperform” rating and cut their price target for the company from $9.00 to $8.00 in a report on Friday, September 10th. Zacks Investment Research cut Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 13th. Finally, Oppenheimer reaffirmed a “buy” rating and issued a $35.00 price target on shares of Inovio Pharmaceuticals in a report on Friday, July 2nd. Three analysts have rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Inovio Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $14.13.

Hedge funds have recently bought and sold shares of the business. UBS Group AG increased its stake in Inovio Pharmaceuticals by 88.5% during the first quarter. UBS Group AG now owns 108,041 shares of the biopharmaceutical company’s stock worth $1,003,000 after acquiring an additional 50,726 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of Inovio Pharmaceuticals by 2.3% during the first quarter. Principal Financial Group Inc. now owns 76,723 shares of the biopharmaceutical company’s stock worth $712,000 after buying an additional 1,694 shares during the period. Valley National Advisers Inc. boosted its position in shares of Inovio Pharmaceuticals by 18.8% during the second quarter. Valley National Advisers Inc. now owns 13,900 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 2,200 shares during the period. Oppenheimer & Co. Inc. purchased a new position in shares of Inovio Pharmaceuticals during the second quarter worth $114,000. Finally, State of Wisconsin Investment Board boosted its position in shares of Inovio Pharmaceuticals by 13.4% during the first quarter. State of Wisconsin Investment Board now owns 249,300 shares of the biopharmaceutical company’s stock worth $2,314,000 after buying an additional 29,500 shares during the period. 34.43% of the stock is owned by institutional investors.

NASDAQ INO opened at $7.86 on Friday. The company has a market cap of $1.65 billion, a PE ratio of -11.39 and a beta of 0.62. The stock’s 50 day simple moving average is $8.44 and its 200-day simple moving average is $8.42. Inovio Pharmaceuticals has a 1-year low of $5.81 and a 1-year high of $19.00. The company has a debt-to-equity ratio of 0.03, a current ratio of 10.48 and a quick ratio of 10.48.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline include VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B.

Featured Article: How to Invest in an Index Fund

Get a free copy of the Zacks research report on Inovio Pharmaceuticals (INO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.